Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.

Stephanie L HoFang NiuSuresh PolaFernando S VelayosXian NingRita L Hui

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)

There was no increased risk of (1) disease worsening requiring acute care or (2) disease worsening requiring acute care or treatment failure in patients with IBD who switched from RP infliximab to infliximab-dyyb when compared to patients who remained on RP infliximab in this US population. Infliximab-dyyb is an option for patients with IBD who need to use RP infliximab.

Keyphrases

ulcerative colitis
acute care
patients with inflammatory bowel disease
randomized controlled trial
systematic review
replacement therapy